JP2000515370A5 - - Google Patents

Download PDF

Info

Publication number
JP2000515370A5
JP2000515370A5 JP1998505608A JP50560898A JP2000515370A5 JP 2000515370 A5 JP2000515370 A5 JP 2000515370A5 JP 1998505608 A JP1998505608 A JP 1998505608A JP 50560898 A JP50560898 A JP 50560898A JP 2000515370 A5 JP2000515370 A5 JP 2000515370A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998505608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000515370A (ja
JP4177457B2 (ja
Filing date
Publication date
Priority claimed from GBGB9614871.3A external-priority patent/GB9614871D0/en
Application filed filed Critical
Publication of JP2000515370A publication Critical patent/JP2000515370A/ja
Publication of JP2000515370A5 publication Critical patent/JP2000515370A5/ja
Application granted granted Critical
Publication of JP4177457B2 publication Critical patent/JP4177457B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50560898A 1996-07-15 1997-07-08 膜結合剤と可溶性ペプヂド性化合物の結合体 Expired - Fee Related JP4177457B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9614871.3A GB9614871D0 (en) 1996-07-15 1996-07-15 Compounds
GB9614871.3 1996-07-15
PCT/EP1997/003715 WO1998002454A2 (en) 1996-07-15 1997-07-08 Conjugates of soluble peptidic compounds with membrane-binding agents

Publications (3)

Publication Number Publication Date
JP2000515370A JP2000515370A (ja) 2000-11-21
JP2000515370A5 true JP2000515370A5 (Direct) 2005-07-14
JP4177457B2 JP4177457B2 (ja) 2008-11-05

Family

ID=10796956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50560898A Expired - Fee Related JP4177457B2 (ja) 1996-07-15 1997-07-08 膜結合剤と可溶性ペプヂド性化合物の結合体

Country Status (17)

Country Link
US (3) US6713606B1 (Direct)
EP (1) EP0912730B1 (Direct)
JP (1) JP4177457B2 (Direct)
AR (1) AR007737A1 (Direct)
AT (1) ATE419345T1 (Direct)
AU (1) AU732725B2 (Direct)
CA (1) CA2260288A1 (Direct)
CO (1) CO4750673A1 (Direct)
DE (1) DE69739186D1 (Direct)
DK (1) DK0912730T3 (Direct)
ES (1) ES2321245T3 (Direct)
GB (1) GB9614871D0 (Direct)
IL (3) IL128034A0 (Direct)
NZ (1) NZ333722A (Direct)
TW (1) TW538048B (Direct)
WO (1) WO1998002454A2 (Direct)
ZA (1) ZA976216B (Direct)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9704519D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Compounds
JP2001525341A (ja) 1997-11-28 2001-12-11 ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 活性ヘッジホッグタンパク質変異体、その調製方法及び医薬への適用
EP1557427A3 (en) 1998-04-30 2005-10-19 Curis, Inc. Hedgehog protein conjugate
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
GB0016811D0 (en) * 2000-07-07 2000-08-30 Adprotech Ltd Lipid rafts
GB0026924D0 (en) 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
GB0117193D0 (en) * 2001-07-13 2001-09-05 Adprotech Ltd Protein modification reagents
GB0123262D0 (en) * 2001-09-27 2001-11-21 Adprotech Ltd Polymeric compounds
GB0220936D0 (en) * 2002-09-05 2002-10-23 Adprotech Ltd Modified therapeutic agents
FR2854897B1 (fr) * 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
US7858108B2 (en) * 2003-10-21 2010-12-28 Richard Nagler Elutable surface coating
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
CA2565886A1 (en) 2004-05-27 2005-12-08 Gropep Limited Treatment of inflammatory airway disease
EP1945658A4 (en) * 2005-09-22 2012-05-30 Yeda Res & Dev DIASTEREOMERS PEPTIDES FOR MODULATING T-CELL IMMUNITY
WO2007103548A2 (en) 2006-03-09 2007-09-13 Inflazyme Pharmaceuticals Ltd. Novel antibiotic compositions
WO2008048675A2 (en) 2006-10-20 2008-04-24 Celldex Therapeutics, Inc. Treatment for age-related macular degeneration and other diseases of the eye
EP2134373A4 (en) 2007-02-28 2014-04-02 Yeda Res & Dev CORE TARGETING SEQUENCES
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CA2751673A1 (en) * 2009-02-20 2010-08-26 Ipsen Pharma S.A.S Analogues of neuropeptide y having proline substitution at position 34
US9428564B2 (en) 2009-04-16 2016-08-30 Universitatsklinikum Heidelberg Muscle function enhancing peptide
GB0915519D0 (en) 2009-09-04 2009-10-07 King S College London Ntithrombotic compounds
WO2011050334A1 (en) * 2009-10-22 2011-04-28 Yong Zhu Compositions and methods for re-programming cells without genetic modification for treatment of obesity and related diseases
AU2011301996A1 (en) 2010-09-15 2013-03-21 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
EP2632476B1 (en) 2010-10-27 2017-06-14 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
GB201402267D0 (en) 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN110240656A (zh) * 2019-04-24 2019-09-17 中山大学附属第三医院 一种融合蛋白及其制备方法与应用
CN110551177A (zh) * 2019-08-29 2019-12-10 安徽瑞达健康产业有限公司 多肽、多肽衍生物、多肽-抗体复合物及制备、应用
GB201913804D0 (en) 2019-09-25 2019-11-06 Prostate Cancer Res Centre Fusion polypeptides
WO2024092160A2 (en) * 2022-10-26 2024-05-02 Flagship Pioneering Innovations Vii, Llc Bifunctional proteases and uses thereof
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536391A (en) 1982-11-17 1985-08-20 Otsuka Pharmaceutical Co. Process for preparing urokinase complex
DE3485094D1 (de) 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
GB8334498D0 (en) 1983-12-24 1984-02-01 Beecham Group Plc Compounds
GB8400653D0 (en) 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
ES8801374A1 (es) 1985-04-04 1988-01-01 Beecham Group Plc Un procedimiento para preparar un activante de plasminogeno.
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
JP2573007B2 (ja) * 1987-12-28 1997-01-16 株式会社成和化成 修飾された動物毛粉末
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5326700A (en) 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
JP3939747B2 (ja) * 1992-06-24 2007-07-04 アドプロテック・リミテッド 可溶性ｃｒ１誘導体
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
PT730608E (pt) * 1993-05-17 2002-09-30 Avant Immunotherapeutics Inc Composicoes compreendendo hidratos de carbono e proeinas relacionadas pelo complemento e metodos para produzir e utilizar as referidas composicoes
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
AU683158B2 (en) * 1994-03-03 1997-10-30 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US5776689A (en) 1996-07-19 1998-07-07 The Regents Of The University Of California Protein recruitment system
AU5994099A (en) 1998-10-01 2000-04-26 Urmas Arumae A novel ret-independent signaling pathway for gdnf
GB0220936D0 (en) * 2002-09-05 2002-10-23 Adprotech Ltd Modified therapeutic agents

Similar Documents

Publication Publication Date Title
JP2000502280A5 (Direct)
JP2000501771A5 (Direct)
JP2000501599A5 (Direct)
JP2000501018A5 (Direct)
JP2000500076A5 (Direct)
JP2000501324A5 (Direct)
JP2000500055A5 (Direct)
JP2000502472A5 (Direct)
JP2000501825A5 (Direct)
JP2000501338A5 (Direct)
JP2000500874A5 (Direct)
JP2000502425A5 (Direct)
JP2000502485A5 (Direct)
JP2000502568A5 (Direct)
JP2000501774A5 (Direct)
JP2000500912A5 (Direct)
JP2000502570A5 (Direct)
JP2000515370A5 (Direct)
JP2000501876A5 (Direct)
JP2000501744A5 (Direct)
JP2000501229A5 (Direct)
JP2000502316A5 (Direct)
JP2000500857A5 (Direct)
JP2000502714A5 (Direct)
JP2000501569A5 (Direct)